A federal appeals court has upheld the convictions and prison sentences of four pharmacists from Michigan and Ohio who operated a massive healthcare fraud scheme, defrauding taxpayers and insurers out of more than $13 million.
The Scheme
The pharmacists, Raef Hamaed, Kindy Ghussin, Ali Abdelrazzaq, and Tarek Fakhuri, used five independent pharmacies across Michigan and Ohio to bill health insurance providers for prescription medications that were never actually dispensed to patients.
The targeted insurers included private companies like Blue Cross Blue Shield of Michigan, as well as Medicare and Medicaid. The pharmacists deliberately targeted patients who were known to be noncompliant with their medication regimens, and when patients failed to pick up their filled prescriptions, they would keep the cash instead of canceling the claim and returning the money to the insurance company.
Concealing the Fraud
To conceal the missing medications during routine audits, the co-conspirators forged patient signatures on pickup logs and kept a designated stash of labels for the prescriptions that were never handed over. They also routinely waived expensive co-pays to drum up more business and, in at least one pharmacy location, secretly swapped out costly brand-name drugs for cheaper generics while still billing for the premium product.
The payouts were massive, with the pharmacists receiving thousands of dollars each month in profit-sharing checks. The scheme ultimately collapsed after Qlarant, an organization contracted by the federal government to investigate healthcare fraud, noticed major discrepancies between the pharmacies’ wholesaler invoices and their billing claims.
Convictions and Sentences
A jury convicted the men of conspiracy to commit healthcare fraud and wire fraud. Hamaed was handed a 120-month prison sentence, Fakhuri received 84 months, Ghussin got 65 months, and Abdelrazzaq was sentenced to 24 months. The court also ordered joint-and-several restitution totaling over $13 million.
During the appeals process, the defense attorneys argued heavily against the use of the fraud investigator’s testimony, but the Sixth Circuit panel rejected all constitutional and procedural challenges, concluding the trial was fair, the evidence of a single overarching conspiracy was solid, and the calculated financial losses were accurate.
Original reporting: Tampa Free Press — read the source article.
